OTCMKTS:RDGL Vivos (RDGL) Stock Price, News & Analysis $0.09 0.00 (0.00%) (As of 11/20/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort Interest About Vivos Stock (OTCMKTS:RDGL) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Vivos alerts:Sign Up Key Stats Today's Range$0.09▼$0.1050-Day Range$0.09▼$0.1852-Week Range$0.05▼$0.26Volume1.55 million shsAverage Volume1.26 million shsMarket Capitalization$37.54 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewVivos Inc., a radiation oncology medical device company, develops brachytherapy devices for the treatment of non-resectable tumors in the United States. It develops yttrium-90 based RadioGel device, an injectable particle-gel for brachytherapy radiation treatment of cancerous tumors in people and animals; and IsoPet for the treatment of solid tumors in animals. The company was formerly known as Advanced Medical Isotope Corporation and changed its name to Vivos Inc. in December 2017. Vivos Inc. was incorporated in 1994 and is headquartered in Richland, Washington.Read More… Tesla Execs are Freaking Out (Ad)It’s so revolutionary that tech giants like Microsoft, Amazon, and NVIDIA are all lining up to get their hands on it. And Elon Musk has completely restructured Tesla to chase this opportunity. This is a once-in-a-lifetime opportunity that you don’t want to miss.Click here to get the details. Vivos Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks22nd Percentile Overall ScoreRDGL MarketRank™: Vivos scored higher than 22% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Vivos. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Vivos is -8.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vivos is -8.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.00% of the outstanding shares of Vivos have been sold short.Short Interest Ratio / Days to CoverVivos has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Vivos has recently decreased by 97.00%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVivos does not currently pay a dividend.Dividend GrowthVivos does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.00% of the outstanding shares of Vivos have been sold short.Short Interest Ratio / Days to CoverVivos has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Vivos has recently decreased by 97.00%, indicating that investor sentiment is improving significantly. News and Social Media3.2 / 5News SentimentN/A News SentimentVivos has a news sentiment score of 1.83. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Finance companies.News Coverage This WeekMarketBeat has tracked 1 news article for Vivos this week, compared to 0 articles on an average week. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Vivos insiders have not sold or bought any company stock.Percentage Held by Insiders18.50% of the stock of Vivos is held by insiders. A high percentage of insider ownership can be a sign of company health.Read more about Vivos' insider trading history. Receive RDGL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vivos and its competitors with MarketBeat's FREE daily newsletter. Email Address RDGL Stock News HeadlinesVivos Therapeutics eyes positive cash flow as it continues cost-reduction success in Q3November 14, 2024 | proactiveinvestors.comVivos Inc. Certifies New Clinic for IsoPet® Precision Radionuclide TherapyTMOctober 18, 2024 | globenewswire.comWhen it comes to NVDA… “acceleration cycles” are the keyExpert options trader Graham Lindman has been working on a new way to tap into Nvidia’s options… By simply isolating outsized “acceleration cycles” within Nvidia stock (most investors don’t even know it exists)... And thanks to many months and late nights working out the kinks of the systems… They have finally found a way to target these cycles on Nvidia over and over again.November 21, 2024 | DTI (Ad)Vivos Inc. Extended its IsoPet® Precision Radionuclide TherapyTM to ExoticsSeptember 30, 2024 | finance.yahoo.comVivos Inc. (RDGL) Stock Price, News, Quote & History - Yahoo FinanceAugust 26, 2024 | finance.yahoo.comVivos Inc. Provides IDE Submission Status Update – Conversion to Pre-Sub Filing Accepted by the FDAJuly 29, 2024 | globenewswire.comVivos Inc. Submits the Application to the FDA for Authority to Initiate Human Clinical TrialsJune 28, 2024 | globenewswire.comVivos Inc. (RDGL) Latest Stock News & Headlines - Yahoo FinanceMay 15, 2024 | finance.yahoo.comSee More Headlines RDGL Stock Analysis - Frequently Asked Questions How have RDGL shares performed this year? Vivos' stock was trading at $0.0723 at the start of the year. Since then, RDGL stock has increased by 24.3% and is now trading at $0.0899. View the best growth stocks for 2024 here. How do I buy shares of Vivos? Shares of RDGL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Vivos own? Based on aggregate information from My MarketBeat watchlists, some other companies that Vivos investors own include MannKind (MNKD), Agenus (AGEN), APA (APA), Aphria (APHA), Bionano Genomics (BNGO), Churchill Capital Corp IV (CCIV) and Canopy Growth (CGC). Company Calendar Today11/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorFinance Industry Surgical & medical instruments Sub-IndustryMedical Equipment Current SymbolOTCMKTS:RDGL CUSIPN/A CIK1449349 Webwww.radiogel.com Phone(509) 736-4000Fax509-736-4007Employees1Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-2,890,000.00 Net MarginsN/A Pretax Margin-12,345.83% Return on EquityN/A Return on Assets-197.34% Debt Debt-to-Equity RatioN/A Current Ratio25.48 Quick Ratio25.48 Sales & Book Value Annual Sales$20,000.00 Price / Sales1,876.87 Cash FlowN/A Price / Cash FlowN/A Book Value($0.02) per share Price / Book-4.49Miscellaneous Outstanding Shares417,593,000Free Float340,338,000Market Cap$37.54 million OptionableNot Optionable Beta1.07 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report This page (OTCMKTS:RDGL) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vivos Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vivos With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.